checkAd
    Startseite > Aktien > Dianthus Therapeutics > Nachrichten
    Dianthus Therapeutics Aktie
    21,610
     
    USD
    +4,40 %
    +0,910 USD
    Letzter Kurs 02:00:00 Nasdaq
    21,500
     
    USD
    300 STK
    Geldkurs 31.05.24
    21,660
     
    USD
    500 STK
    Briefkurs 31.05.24
    ISIN: US2528281080 · WKN: A3ERZ4 · SYM: DNTH · USA

    Neueste Nachrichten

    Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
    30.05.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
    09.05.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
    08.05.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.05.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
    11.04.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.04.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
    21.03.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    07.03.24 · globenewswire · Dianthus Therapeutics
    Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
    26.02.24 · globenewswire · Dianthus Therapeutics
    Dianthus-Aktie: +177% nach Reverse Merger für den NBC!
    26.01.24 · Sharedeals · Dianthus Therapeutics
    MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
    07.08.23 · Business Wire (engl.) · Dianthus Therapeutics